May 04, 2024 – Everest Pharma is pleased to announce the launch of RUXOTOR Tablets, a cost-effective generic version of the FDA-approved JAKAFI® (Ruxolitinib Tablets). This launch marks a significant milestone in the treatment of serious hematologic disorders, including polycythemia vera, myelofibrosis, and steroid-refractory acute graft-versus-host disease (GVHD).
RUXOTOR Tablets contain Ruxolitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor that interferes with overactive signaling involved in several chronic hematologic conditions. The drug is indicated for adults with intermediate or high-risk myelofibrosis, for patients with polycythemia vera who are resistant or intolerant to hydroxyurea, and for acute GVHD in patients aged 12 years and older who have not responded to corticosteroid therapy.
Originally approved by the U.S. FDA on December 4, 2014, for the treatment of polycythemia vera, Ruxolitinib marked a breakthrough in targeted therapies for bone marrow diseases. With the introduction of RUXOTOR Tablets, Everest Pharma aims to bring the benefits of this essential therapy to a broader population by making it more affordable and accessible—particularly in regions where treatment costs can be a barrier to care.
“Our launch of RUXOTOR Tablets reflects Everest Pharma’s ongoing commitment to delivering innovative and accessible medicines that meet the needs of patients with life-altering conditions,” said Mr. Md. Zakir Hossain, Managing Director of Everest Pharma. “This addition to our hematology portfolio strengthens our dedication to improving patient outcomes and expanding global access to critical therapies.”
RUXOTOR Tablets offer the same high-quality formulation and therapeutic performance as the reference product, ensuring that physicians and patients can rely on its efficacy and safety. As Everest Pharma continues to grow its footprint in specialty and oncology care, the introduction of RUXOTOR underscores its leadership in delivering trusted, affordable alternatives to complex treatments.
The availability of RUXOTOR Tablets (Generic of JAKAFI) is expected to play a pivotal role in transforming care for patients battling chronic hematologic disorders, reaffirming Everest Pharma’s position as a key innovator in high-impact therapeutic areas.
About Everest Pharma:
Everest Pharma is a globally recognized pharmaceutical company committed to offering high-quality, affordable generic medicines. With a focus on innovation and access, the company continues to develop essential therapies across a range of therapeutic areas to improve patient outcomes worldwide.
For more information on RUXOTOR and Everest Pharma’s portfolio, visit https://www.ruxotor.com/ or https://www.everestpharmabd.com/
